F Biosciences appoints Farhan Rafique new CEO

BF Biosciences Limited (PSX: BFBL) has appointed Muhammad Farhan Rafique as its new Chief Executive Officer, effective January 1, 2026, following the resignation of founding CEO Akhter Khalid Waheed.

According to a notice submitted to the Pakistan Stock Exchange, the Board of Directors accepted Waheed’s resignation during an emergent meeting on December 19, 2025.

The Board also expressed appreciation for her contributions in establishing and expanding the company.

Under Waheed’s leadership, BF Biosciences evolved into a recognized name in Pakistan’s pharmaceutical sector, achieving sustained growth, operational excellence, and strategic expansion.

Rafique, previously served as the company’s Chief Operating Officer, played a pivotal role in executing major initiatives under Waheed’s leadership. 

His work includes leading the company’s brownfield expansion, supporting a successful Initial Public Offering (IPO), and driving digital transformation across operations.

With over 14 years of experience in the pharmaceutical industry, Rafique has held various leadership positions and brings operational insight, strategic vision, and execution capability to his new role. 

The Board stated that his appointment will ensure continuity in leadership while building on the foundation established by the founding CEO.

BF Biosciences Limited remains listed on the Pakistan Stock Exchange and continues its focus on healthcare solutions and market expansion.

The company aims to create long-term value for its stakeholders amid a competitive pharmaceutical market in Pakistan.